Ronaldo stake and refinancing plans put Herbalife in focus
Herbalife (HLF) has jumped into the spotlight after Cristiano Ronaldo took a US$7.5 million, 10% stake in its health tech subsidiary, paired with fresh refinancing plans and a recent earnings beat.
See our latest analysis for Herbalife.
At a share price of US$19.24, Herbalife has seen a 54.54% 3 month share price return and a 50.08% year to date share price return. The 1 year total shareholder return of 137.24% contrasts with a weaker 3 year and 5 year total shareholder return, suggesting that recent momentum has picked up after a tougher longer term run. Recent interest around the Ronaldo stake, the refinancing announcement and the latest earnings report all add context to why shorter term sentiment has shifted.
If this kind of turnaround story has your attention, it could be a good moment to broaden your search with our list of 19 top founder-led companies as potential ideas to research next.
With Herbalife trading near US$19 despite an intrinsic value estimate that implies roughly a 39% discount and a recent surge driven by Ronaldo headlines and refinancing news, is there still a genuine buying opportunity here, or has the market already priced in future growth?
Most Popular Narrative: 37.4% Overvalued
With Herbalife closing at $19.24 against a fair value estimate of $14, the most followed narrative sees the shares trading well ahead of its modelled worth, built on a detailed view of growth, margins and risk.
The analysts have a consensus price target of $9.333 for Herbalife based on their expectations of its future earnings growth, profit margins and other risk factors. However, there is a degree of disagreement amongst analysts, with the most bullish reporting a price target of $11.0, and the most bearish reporting a price target of just $7.0.
Read the complete narrative. Read the complete narrative.
Want to see how this fair value hangs together? Revenue ticking up, margins shifting, and the implied future earnings multiple all pull in different directions. Curious which assumptions really move the needle in this model.
Result: Fair Value of $14 (OVERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, strong execution on its wellness tech push and a sustained improvement in margins could challenge this overvalued view and reset expectations around the earnings power of Herbalife.
Find out about the key risks to this Herbalife narrative.
Another View: Earnings Multiple Sends a Different Signal
While the most followed narrative sees Herbalife as 37.4% overvalued against a US$14 fair value, the current P/E of 8.7x paints a different picture. That is far below the estimated fair ratio of 14.4x and also well under peers at 56.9x. This points to meaningful valuation risk if sentiment turns, but also clear upside potential if the market moves closer to that fair ratio. Which signal do you think will matter more over time: the modelled fair value or the earnings multiple gap?
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
The mix of enthusiasm and caution here is clear. If this story interests you, take a closer look at the full picture and weigh both sides, including 3 key rewards and 2 important warning signs.
Looking for more investment ideas?
If Herbalife has you thinking more broadly about your portfolio, do not stop here. The next opportunity you research could be the one that really matters.
- Target potential mispricing by checking stocks our screener flags as 46 high quality undervalued stocks backed by solid fundamentals and clear financial data.
- Prioritise strength by reviewing companies in the solid balance sheet and fundamentals stocks screener (41 results) that focus on resilient finances and lower funding risk.
- Hunt for fresh potential by scanning our screener containing 24 high quality undiscovered gems that the market may not be paying close attention to yet.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com